New Colon Cancer Study Results Reported from Roswell Park Comprehensive Cancer Center

Strategic Insights -

Researchers at the Roswell Park Comprehensive Cancer Center have reported positive results from a phase II clinical trial examining the efficacy of TAS-102, irinotecan, and bevacizumab in treating patients with pre-treated, advanced colorectal adenocarcinoma. The study found that the combination of these three treatments resulted in a median progression-free survival (PFS) of 7.9 months and a median overall survival (OS) of 16.5 months.

Key Takeaways:

  • The efficacy of FOLFIRI plus an antiangiogenesis biologic agent as 2nd line therapy for metastatic colorectal adenocarcinoma is limited.
  • TAS-102 is a novel oral antimetabolite with a distinct mechanism of action from fluoropyrimidines.
  • The combination of TAS-102, irinotecan, and bevacizumab resulted in a median PFS of 7.9 months and a median OS of 16.5 months.
  • Sixty-seven percent of patients experienced grade 3 or higher treatment-related adverse events, with hematological and gastrointestinal toxicities being the most common.
  • The study concluded that a randomized study versus standard-of-care therapy is warranted.
  • Researchers included Sarbajit Mukherjee, Patrick M. Boland, Iman Imanirad, Namrata Vijayvergia, and others.
  • The study was published in the British Journal of Cancer.

Statistics:

  • Median PFS: 7.9 months (90% CI 6.2-11.8)
  • Median OS: 16.5 months (90% CI 9.8-17.5)
  • Percentage of patients experiencing grade 3 or higher treatment-related adverse events: 67%
  • Most common toxicities: hematological (neutropenia) and gastrointestinal (diarrhoea, nausea, and vomiting)

Sources:

  • NewsRx. New Colon Cancer Study Results Reported from Roswell Park Comprehensive Cancer Center [TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial]. Immunotherapy Weekly. September 24, 2025; p 1480.
  • British Journal of Cancer. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. British Journal of Cancer, 2024;131(8):1290-1297.